Drugs / PostbiotiX-HLA
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07485296 | Jan 2026 → Dec 2030 expected | head and neck squamous cell carcinoma | Gruppo Oncologico del Nord-Ovest | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07050940 | Feb 2025 → Aug 2026 overdue | metastatic melanoma | Azienda Ospedaliera di Perugia | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Postbiotix-HLA | “Postbiotix-HLA™, 1 capsule (400 mg) daily PO from cycle 1 day 1 up to cycle 5 day1 (i.e. 4 cycles)” NCT07485296 ↗1“postbiotic food supplement PostbiotiX-HLA 1 capsule (200mg) /day” NCT07050940 ↗ |
| Modality | Other / unclassified | “postbiotic food supplement PostbiotiX-HLA 1 capsule (200mg) /day” NCT07050940 ↗ |
| Route | Oral | “1 capsule (400 mg) daily PO” NCT07485296 ↗ |